Tag: Covishield

  • Rs 600 per dose for states, Rs 1200 to private hospitals: Bharat Biotech releases rates for Covaxin

    By Express News Service
    NEW DELHI: Hyderabad-based Bharat Biotech on Saturday announced that its COVID-19 vaccine, Covaxin will cost Rs 600 per dose to state governments and Rs 1200 per dose to private hospitals, two days after its competitor Serum Institute of India declared the rate of Covishield for non-central government channels.

    Covaxin and Covishield are currently two available vaccines for COVID-19 in India.

    SII had said that Covishield will be available to states at Rs 400 per dose and private hospitals at Rs 600 per dose which led to huge criticism as the company has hinted earlier that it was generating normal profit even at Rs 150 per dose, at which it has been supplying the vaccine to the Centre.

    Here is @BharatBiotech ‘s justification for the steep price of Covaxin at Rs 600 per dose to states, Rs 1200 per dose to private hospitals #COVID19 #COVIDEmergency2021 pic.twitter.com/zBbe5dnGlR
    — Sumi Dutta (@SumiSukanya) April 24, 2021

    In a statement, Bharat Biotech, which has developed Covaxin in collaboration with ICMR’s National Institute of Virology said that the company is “honoured to develop, manufacture and supply the vaccine for India’s vaccine rollout at Rs 150 per dose”, which is distributed for free by the Centre.

    “We would like to state that more than 50 per cent of our capacities have been reserved for Central government supplies,” it said adding that the vaccine has a distinct feature of having a 28 day open vial policy. Once opened, the vaccine can be stored at 2-8 degree Celsius for 28 days thereby reducing the wastage.

    A thread on Bharat Biotech’s (BB) pricing of Covaxin at Rs 600/dose for State governments and Rs 1200/dose for private hospitals. The pricing of Covaxin at prices higher than Covishield puts the so-called Indian vaccine even more out of bounds for the poorer Indian citizens. 1/n
    — R. Ramakumar (@ramakumarr) April 25, 2021

    The announcement comes days after the company, along with ICMR, issued a press release saying that the second interim analysis of the phase-3 clinical trial of the vaccine had shown it to be 78 per cent effective against infection and 100 per cent effective against severe disease.

    The company also justified the price, viewed as steep by many, by saying that Covaxin is an inactivated and highly purified vaccine, making manufacturing expensive due to very low process yield. “All costs towards product development, manufacturing facilities and clinical trials were deployed primarily using internal funding and resources of Bharat Biotech,” said the company.

    It also said that “recovering costs is essential in the journey of innovation towards other vaccine such as intranasal COVID-19, Zika, Chikungunya, Cholera and others”.

  • Modi govt’s vaccine policy allowing Serum Institute to earn ‘super profits’: Experts

    Express News Service
    NEW DELHI: The new Covid vaccination strategy, announced earlier this week, has allowed the Serum Institute of India (SII), a private firm, to dominate the vaccine pricing and policy and earn super profits, experts have pointed out.

    It is also in contradiction of an earlier stated stand by the National Expert Group on Vaccination Administration for Covid, which was in the favour of a single point of procurement for vaccines, many felt.

    The shift in the policy by the Centre now means that states and private hospitals can directly procure 50% of the supplies from vaccine makers while the Centre will aim its drive to fund jabs for those above 45 at select vaccination centres.

    SII, whose product, Covishield, has been the linchpin of India’s Covid vaccination drive so far with over 90% share in total 13 crore plus shots administered so far, has said that it will make available the vaccine at Rs 400 per dose to states and Rs 600 per shot to hospitals from May 1 when all adults in the country will qualify for inoculations.

    The company had signed an agreement to supply nearly 11 crore vaccine doses — between January to April — at Rs 150 per dose to the Centre and its CEO Adar Poonawalla in an interview earlier had indicated that it was recovering the production cost at that rate and was even making normal profit.

    The latest pricing announcement, however, makes it clear that the company is now looking to earn a greater margin on the vaccine, originally developed by AstraZeneca-Oxford University through 97% public funding by the UK government and the European Union.

    SII had earlier announced that it would want to sell Covishield at Rs 1,000 per dose in the private market, pointed out R Ramkumar, an economist with the Tata Institute of Social Sciences in Mumbai who has been closely following the development.

    “Perhaps it could not do it in one go but is clearly looking to maximise its profit and the Centre has succumbed under the pressure,” he said.

    He also stressed that the government, even considering that the vaccine will now cost Rs 400 per dose, will have to spend just Rs 53,000 crore—or 0.2% of the GDP—to incolutate the entire adult population with two doses.

    ALSO READ | Preliminary study shows Covishield protects against double mutant strain: CCMB director Rakesh Mishra

    “Why should the government shy away from doing that in the large public good and lead to a chaos that is about to unfold once states starting vying for the vaccine during a pandemic situation?” he asked.

    Epidemiologist Jammi N Rao dubbed the policy of having two or even 3 different prices for different purchasers as “mad”.

    “From a fiscal point of view state or central government makes no difference, it is ultimately the same taxpayer funded pot of money,” he said and made four points to argue against a system of multiple channels of procurement and differential pricing.

    Firstly, it breaches the principle of universality, Rao said.

    “There is now almost unanimous agreement that a quick and efficient programme of vaccinating the majority of the population offers the best, perhaps the only, means of escaping the chokehold exerted by waves of Covid-19 cases on normal life and economic activity,” he reckoned.

    Secondly, if states are forced to do their own procurement at an additional cost they may well be pushed into charging people for the service, Rao argued saying that it will create a new disincentive for people already impoverished by the economic slump and loss of livelihoods according to him.  

    Also, said Rao, by allowing manufacturers to set their own prices, the country loses the ability of bulk procurement and price negotiations to get the most cost-effective deal.

    The fourth argument put forth by him is that the new procurement policy subtly glosses over the cash injection that the Indian taxpayer has made into the two main vaccine manufacturers—the other one being Bharat Biotech.

     Finance Minister Nirmala Sitharaman had two days back announced that the Centre would fund capacity expansion to the tune of Rs 3000 crores to Serum Institute and Rs 1575 Rs crores to Bharat Biotech.

    “While this is absolutely to be welcomed, one should remember that this cash injection was on behalf of the Indian tax-payer. It is justified therefore to expect that the Indian government — it makes no difference whether it is Centre or states gets a preferential price for the vaccines that the extra capacity will produce,” Rao stressed.

    Some others meanwhile expressed dismay at the SII decision to introduce differential pricing for governments and the private market.

    “I strongly disagree with that unilateral decision,” said K V Babu of the Association of Doctors for Ethical Healthcare. 

  • Vaccine registration for adults from April 28, states free to procure jabs from manufacturers

    By Express News Service
    NEW DELHI:  On a day India reported over 3 lakh fresh cases, the highest daily global total tally, the Centre announced that the registration for Covid vaccination will begin from April 28 to carry out inoculations of all adults in the country.

    Vaccination for all above 18 years starts from May 1.

    “It is clarified that #CoWin portal will be made ready for 18+ beneficiaries by 24th April. Registrations for 18+ citizens to book appointments (from 1st May) will begin on 28th April,” the health ministry tweeted.

    From May 1, the present system of private COVID-19 vaccination centres receiving doses from the government and charging up to Rs 250 per dose will cease to exist and private hospitals will procure directly from vaccine manufacturers.

    The government, however, also made it clear that vaccination for those in the 18-45 years will be provided by the states or in the private sector while it will fund vaccination for only those above 45 at designated centres from the next month by procuring 50 % of all the vaccine supplies directly.

    According to the Liberalised Pricing and Accelerated National COVID-19 Vaccination Strategy, COVID-19 vaccination will continue to be free for eligible population groups comprising healthcare workers, frontline workers and people above 45 years of age in government vaccination centres, which receive doses from the government of India.

    Vaccine manufacturers would make an advance declaration of the price for 50 per cent supply that would be available to state governments in the open market before May 1.

    Based on this price, states, private hospitals, industrial establishments may procure vaccine doses from manufacturers.

    Private hospitals would have to procure their supplies of COVID-19 vaccine exclusively from the 50 per cent supply earmarked for other than the government of India channel.

    “While the Centre has liberalised the vaccination policy, it does not mean that vaccines will be sold in pharmacists or chemist shops in the open market,” health secretary Rajesh Bhushan had clarified on Wednesday.

    The price charged for vaccination by private hospitals would be monitored, he said.

    “The present dispensation where private COVID vaccination centres receive doses from the government and can charge up to Rs 250 per dose will cease to exist,” the Union health ministry said.

    Vaccine manufacturers would supply 50 per cent of their monthly Central Drugs Laboratory (CDL) released doses to the government of India and would be free to supply the remaining 50 per cent doses to state governments and in the open market.

    For government of India vaccination centres, the eligible population would be the same, which exists today, that is healthcare workers (HCWs), frontline workers (FLWs) and population above 45 years of age.

    For other than the government of India channel, the eligibility would be all adult citizens of the country, the document said.

    Vaccination against COVID-19 will continue to be free for eligible population groups in all those government COVID vaccination centres which receive vaccine doses from the central government.

    All vaccination (through government of India vaccination centres and other than the government of India channel) will be part of the National Vaccination Programme, will follow all existing guidelines, will be captured on the CoWIN platform along with the stocks and price per vaccination applicable in all vaccination centres, will comply with Adverse Event Following Immunization (AEFI) management and reporting, digital vaccination certificate and all other prescribed norms.

    The division of vaccine supply, which would mean 50 per cent to the government of India and 50 per cent to other than the government of India channel would be applicable uniformly across for all vaccines manufactured in the country.

    However, the fully ready to use imported vaccine would be allowed to be utilised entirely in the other than government of India channel, it said.

    The Centre from its share will allocate vaccines to states and union territories based on the criteria of performance (speed of administration, average consumption), extent of infections (number of active COVID-19 cases), the document stated.

    Second dose of all existing priority groups i.e. HCWs, FLWs and people aged above 45, wherever it has become due, would be given priority, for which a specific and focused strategy would be communicated to all stakeholders.

    This policy would come into effect from May 1 and would be reviewed from time-to-time.

    India’s daily jump in cases of 3,14,835 surpasses the previous highest one-day rise in the world of 297,430 cases posted by the US in early January. India’s total cases are now at 15.93 million, while the confirmed have reached 1,84,65.

    Amid reports that Covishield may not be separately available to states till May 25, due to SII’s contract with the Centre till then, the health ministry on Thursday refuted such claims.

    “There have been some media reports suggesting that Serum Institute of India (SII) has contracted all its production till 25th May 2021 to the Centre, and therefore till that date the State governments will not be able to procure vaccine from SII,” said the ministry.

    These media reports are based on incorrect facts and are without any basis, it added. “..it is very clear that every month out of the total CDL(Central Drug Laboratories) cleared doses available with any vaccine manufacturer, 50% doses would be available for other than Government of India channels,” the ministry statement said.

    A key feature of the strategy is that the “vaccine manufacturers would supply 50 per cent of their monthly Central Drugs Laboratory (CDL) released doses to Government of India and would be free to supply remaining 50 per cent doses to state governments and in the other than Government of India channel,” the ministry said.

    The state governments are free to purchase the vaccine doses from vaccine manufacturers, it said.

    “Therefore, it is very clear that every month out of the total CDL cleared doses available with any vaccine manufacturer, 50 per cent doses would be available for other than Government of India channels,” it said.

    Vaccine manufacturers would make an advance declaration of the price for 50 per cent supply that would be available to state governments in the open market before May 1.

    Based on this price, states, private hospitals, industrial establishments may procure vaccine doses from manufacturers.

    Private hospitals would have to procure their supplies of COVID-19 vaccine exclusively from the 50 per cent supply earmarked for other than Government of India channel.

    The price charged for vaccination by private hospitals would be monitored, it said.

    (With PTI Inputs)

  • Preliminary study shows Covishield protects against double mutant strain: CCMB director Rakesh Mishra

    By PTI
    NEW DELHI:  Preliminary results of a study have shown that Covishield vaccine protects against the B.1.617 variant of coronavirus, also known as the double mutant strain, Rakesh Mishra, director of the Centre for Cellular and Molecular Biology said on Thursday.

    He said the study was conducted by the CCMB, an institute of the Council for Scientific and Industrial Research (CSIR).

    “Very preliminary but encouraging result: #Covishield protects against #B1617. Early results using in vitro neutralisation assay show that both convalescent (prior infection) sera and Covishield-vaccinated sera offer protection against the B.1.617 variant, aka #DoubleMutant,” Mishra tweeted.

    However, Mishra was not available for further details.

    Covishield, the Oxford-Astrazeneca COVID-19 vaccine, is manufactured by the Serum Institute of India (SII).

    The B.1.617 variant contains mutations from two separate virus variants, namely E484Q and L452R.

    The double mutant strain was found in saliva samples collected from Maharashtra, Punjab, and Delhi.

    There is apprehension among experts that the new variant could also increase infection rates and easily surpass immune defences.

  • BJP MLA slams Serum India over anti-COVID vaccine pricing, calls its CEO Adar Poonawalla ‘dacoit’

    By PTI
    LUCKNOW: Upset over anti-coronavirus vaccine pricing by the Serum Institute of India (SII), a BJP MLA has compared its CEO Adar Poonawalla with a “dacoit” and asked the government to “acquire” the company under the Epidemic Diseases Act.

    Gorakhpur MLA Radha Mohan Das Agrawal made the remarks after SII on Wednesday announced a price of Rs 600 per dose for Covishield supplies to private hospitals and Rs 400 per dose to state governments.

    “@adarpoonawalla you are worse than a dacoit. @PMOIndia @AmitShah @blsanthosh @drharshvardhan should acquire your factory under the epidemic act,” the MLA, who is also a doctor, said in a tweet in Hindi on Wednesday.

    @adarpoonawalla / तुम तो डकैतों से भी बदतर हो। @PMOIndia @AmitShah @blsanthosh @drharshvardhan को तुम्हारी फैक्टरी का एपिडेमिक ऐक्ट में अधिग्रहण कर लेना चाहिए।@RubikaLiyaquat@pankajjha @aroonpurie @sandeep_news24 @brajeshlive @chitraaum @anjanaomkashyap @PrannoyRoyNDTV
    — Dr.radha mohan das agrawal (@AgrawalRMD) April 21, 2021

    In a series of tweets, Agrawal also referred to the Swaminathan Commission’s formula for agriculture costs and prices.

    The world’s largest vaccine maker announced the pricing of AstraZeneca shots it manufactures at its Pune facility, following the government decided to open up inoculation to all citizens above 18 years of age.

  • New COVID vaccine policy discriminatory: Sonia Gandhi writes to PM Modi

    By PTI
    NEW DELHI: Congress president Sonia Gandhi on Thursday wrote to Prime Minister Narendra Modi over the new COVID-19 vaccine policy, terming it as arbitrary and discriminatory and urged him to intervene immediately to reverse it.

    In a letter to the prime minister, the Congress chief alleged that the new vaccine policy implies that the central government has abdicated its responsibility of providing free vaccine to all Indians between 18 and 45 years of age.

    “It is surprising that despite the harsh lessons of last year and the pain inflicted on our citizens, the Government continues to follow an arbitrary and discriminatory policy, which promises to exacerbate existing challenges,” she said in her letter.

    “The policy implies that the Government of India has abdicated its responsibility to provide free vaccination for citizens between the age group of 18 and 45 years. This is a complete abandonment of the Government’s responsibility towards our youth,” she said.

    Noting that any reasonable person will agree on the benefit of a uniform price for vaccination, she urged prime minister Modi to intervene immediately and “reverse this ill-considered decision”.

    The Centre on Monday announced a liberalized vaccine policy, making all adults above 18 years of age eligible for getting vaccination from May 1.

    The Serum Institute of India on Wednesday announced a price of Rs 400 per dose for its COVID-19 vaccine ‘Covishield’ for state governments and Rs 600 per dose for private hospitals.

  • ‘Centre’s COVID-19 vaccination drive will lead to profiteering by private companies’: Forum

    In a statement, the Progressive Medicos and Scientists Forum, said on Wednesday that the Centre #39;s move is #39;bound to lend the vaccine prices to market manipulation for maximising private profits #39;.

  • Silver lining in India’s COVID fight? Low infection rate after vaccination shot in arm for inoculation drive

    By Express News Service
    NEW DELHI:  Amid concerns that many people are contracting Covid-19 in the current surge of the pandemic despite taking vaccines against it, the Centre on Wednesday released data to show that the number of such breakthrough infections is negligible.

    At a press briefing, ICMR director general Balram Bhargava said only two-four in 10,000 Covid-19 infections post inoculations have been seen in India so far which was minuscule.

    He, however, did not elaborate on whether or how many of these infections led to severe disease or deaths. 

    The contraction of virus after being inoculated with a single or both doses of the vaccine is referred to as post-vaccination breakthrough infection.

    The reassurance on a few instances of breakthrough infections comes ahead of the major expansion of the ongoing vaccination drive that is set to be opened for all adults in the country starting May 1.

    “The narrative on breakthrough infections is distant from reality,” said V K Paul, member (health) of the Niti Aayog who heads the national Covid-19 task force said.

    “The incidence of breakthrough infection is very low. Even if Covid infection occurs after the first and the second dose of the vaccine, it does not cause severe disease. The risk of infection is there which is why masks are important, but the risk of severe infection reduces considerably.” Bhargava pointed out that the available vaccines are most effective mostly after two weeks of the second dose even though immune response could vary from person to person.

    Bhargava said 0.

    04 per cent of 17,37,178 individuals, who received the second dose of Covaxin, were positive for COVID-19, while 0.

    03 per cent of 1,57,32,754 people, who took the second dose of Covishield, contracted the infection.

    Bhargava who presented the data said vaccines reduce the risk of infection and prevent death and severe infection.

    “After vaccination if one gets infection then it is known as breakthrough infection,” he said.

    So far, 1.1 crore doses of Covaxin have been administered.

    Out of which 93 lakh received the first dose and out of that 4,208 (0.04 per cent) people got the infection which is four per 10,000 individuals.

    About 17,37,178 people received the second dose of which only 695 (0.04 per cent) tested positive for COVID-19, Bhargava said.

    Of Covishield, 11.6 crore doses have been given.

    Ten crore received the first dose and 17,145 i.e.2 per 10,000 people contracted the infection.

    About 1,57,32,754 individuals took the second dose of Covishield and of that 5,014 (0.03 per cent) got infected.

    Two to four per 10,000 breakthrough infections have occurred, a very small number.

    This was mainly healthcare workers prone to more occupational hazards, he said.

    According to the data, 5,709 people contracted the infection after the second dose of either of the two vaccines.

    “This is a very small number and not at all worrisome. Secondly, the highly transmissible second wave also contributed (in) miniscule (way) to the percentage so this could have been even zero per cent,” he said.

    Responding to a question that there have been cases of people with no other exposure  testing positive two weeks after vaccination, and if there is any link between vaccine and cases among those vaccinated, Bhargava said these vaccines are given to protect from the disease.

    “These definitely do not cause any disease. However, the immune response takes two dose plus two weeks to fully mount. But individual variations do occur, some may get it slightly earlier some may get a delayed response,” he said.

    NITI Aayog Member (Health) V K Paul noted that there is a risk even after taking vaccination so “we stress people to follow COVID appropriate behaviour even after taking the vaccination”.

    Paul said that with refinements being made in vaccine policy, India is talking to major manufacturers from other countries very, very actively.

    He further said a fourth vaccine, Hyderabad-based Biological E’s indigenous anti -coronavirus shot, may become available from August.

    “The phase 1 and 2 trial of Biological E is almost over and they will be submitting their data, and after that they will go into phase 3. This is a very significant development as they have a capacity of seven crore vaccines per month,” Paul said.

    On vaccinations, Bhushan said 87 per cent of all healthcare workers and 79 per cent of frontline workers have received their first dose of vaccine.

    “Eighty per cent of healthcare workers have received the second dose of vaccine so that is a matter of satisfaction,” he said.

    About 11 states and UTs — Himachal Pradesh, Daman and Diu, Kerala, Rajasthan, Ladakh, Uttarakhand , Bihar, Madhya Pradesh, Chhattisgarh, Jharkhand and Gujarat — have administered first dose to more than 90 per cent of the registered healthcare workers.

    Eleven states and UTs — Nagaland, Chandigarh, Manipur ,Meghalaya, Punjab, Telangana, Lakshadweep, Puducherry, Arunachal Pradesh, Jammu and Kashmir and Delhi — have administered first dose to less than 75 per cent of the registered HCWs.

    Fourteen states and UTs have given second dose to more than 85 per cent of eligible HCWs.

    They are Andhra Pradesh, Karnataka, Dadra and Nagar Haveli, Tripura, Uttarakhand, Jharkhand, Himachal Pradesh, Kerala, Mizoram, Arunachal Pradesh, Goa, Sikkim, Ladakh, Daman and Diu.

    Eight states and UTs — Manipur, Jammu and Kashmir, Tamil Nadu, Assam, Lakshadweep, Maharashtra, Haryana and Delhi — have given second dose to less than 75 per cent of the eligible HCWs.

    Eleven states and  UTs — Himachal Pradesh, Uttar Pradesh, Tripura, Daman and Diu, Uttarakhand, Chhattisgarh, Ladakh, Rajasthan, Madhya Pradesh, Gujarat  and Dadra and Nagar Haveli have administered first dose to more than 80 per cent of the registered FLWs.

    Ten states and UTs with FLW coverage less than 65 per cent are Goa, Nagaland, Manipur, Mizoram,Telangana, Meghalaya, Andaman and Nicobar Islands, Arunachal Pradesh, Chandigarh and Kerala.

    Ten states and UTs have given second dose to more than 84 per cent of eligible FLWs.

    They are Arunachal Pradesh, Rajasthan, Himachal Pradesh, Jharkhand, Chhattisgarh, Telangana, Uttarakhand, Lakshadweep, Uttar Pradesh and Meghalaya.

    Nine states and UTs — Tamil Nadu, Kerala, Andaman and Nicobar Islands, Daman and Diu, Karnataka, Puducherry, Andhra Pradesh, Haryana, Jammu and Kashmir — have given second dose to less than 70 per cent of eligible FLWs.

    Ten states and UTs  — A&N Islands, Uttarakhand, Gujarat, Himachal Pradesh, Rajasthan, Lakshadweep, Chhattisgarh, Tripura, Sikkim and Ladakh — have given first dose to more than 40 per cent of the people aged above 60 years.

    The data presented in the briefing showed that out of the 93,56,436 people who received first doses of Covaxin by Bharat Biotech, 4,208 (0.04%) had a breakthrough infection.

    The proportion was the same for those who received second doses of the indigenously developed Covid19 vaccine as out of 17,37,178 who got the second and final jab, 695 got the infection.

    Similarly, of 10,03,02,745 people who received the first dose of Covishield, 17,145 or 0.02% got a breakthrough infection and out of 1,57,32,754, who got the second dose of this vaccine, 5,014 or 0.03% reported breakthrough infection.

    These figures have been released a week after the Centre for Disease Control in the US said that it had reports of nearly 5,800 breakthrough infections, out of the nearly 77 million individuals in the country who have been vaccinated.

    Experts say such cases are not unexpected as no vaccine is 100% effective against infection but also say that the government should make public the detailed efficacy data of the vaccines being used.

    “It would be good if the government releases detailed real-world efficacy data of the vaccines to show how they are protecting against infections and severe disease and will build confidence in people,” said immunologist Seyed Hasnain.    

    Meanwhile, efforts are being ramped up for massive production of vaccines and make them available in the shortest possible time, a top government official said on Wednesday, stressing that India currently has a promising pipeline of four-five COVID-19 vaccine candidates, while three have already been approved for emergency use.

    Department of Biotechnology Secretary Renu Swarup said a financial support of Rs 400 crore is being provided to vaccine candidates from Zydus Cadilla, Biological E, Gennova and Bharat Biotech (single-dose intranasal vaccine).

    Her statement came days after the government widened the vaccination drive to cover everybody above the 18 years of age.

    “There are three vaccines in India, which have been approved for Emergency Use Authorisation — Covishield by Serum Institute of India (SII), Covaxin by Bharat Biotech International Ltd. (BBIL) and the Russian Vaccine, Sputnik-V. Besides these, there is promising pipeline of 4-5 candidates in advanced clinical stages of development,” Swarup told PTI.

    DNA Vaccine candidate by Zydus Cadila, protein subunit vaccine candidate by BioE, mRNA vaccine candidate by Gennova, and single dose intranasal vaccine candidate by Bharat Biotech are in advanced stages of clinical trials, she said.

    “The Department of Biotechnology has provided technical, advisory and financial support for these vaccine candidates during their early development.

    Now, under Mission COVID Suraksha, financial support of nearly Rs 400 crore for late stage clinical development of these vaccine candidates is being provided.

    “The manufacturers already have existing capacities and can contribute to about 15-20 million doses per month, which can be made available for immunisation, once approved,” Swarup said.

    Six Indian firms including Dr Reddy’s will collectively produce 70 crore doses per annum of Russian vaccine Sputnik V, she added.

    (With PTI Inputs)

  • Possible chaos, greater vaccine inequity due to production shortage: Cons of Modi government’s new policy outweigh pros

    Express News Service
    NEW DELHI:  A day after the Centre liberalised its Covid-19 vaccination policy, allowing states to procure doses directly from the manufacturers for the first time in Indian history, experts worried over the possible chaos and greater vaccine inequity it could create amid vaccine short supply and financial constraints.

    While two vaccines are being used as of now Covishield by Serum Institute of India and Covaxin by Bharat Biotech Russian vaccine Sputnik V is likely to be available in limited amounts in the coming weeks. On Monday, the Centre also made all above 18 years of age eligible for vaccination from May 1.

    In other words, nearly 94 crore in India are now eligible for the vaccine, while the current production is around 80 million per month.

    The new policy allows manufacturers a free hand to sell 50 per cent of their supply to states as well as in the open market at a pre-declared price. But most specialists felt that the new vaccination regime, especially when supply is scarce, could lead to a bigger mess.

    “We have a very well functional and equitable vaccination model in place for many decades under which the Centre procures the vaccines and distributes them among states based on their needs and quota,” former Union health secretary Sujatha K Rao The New Indian Express.

    Some others said that this policy is akin to inviting 100 people for a party even when there is food only for 20.

    A senior public health researcher said that it was very disappointing that of all the vaccination strategies possible, the government had chosen “the worst one”, adding that the private vaccine makers will benefit the most, people, especially the poor, will be the biggest losers.

    “States without any experience in vaccine procurement have been asked to take the programme in their hands. While some of the richer states can manage it to some extent, people in the backward ones will suffer the most.”

    Health economists stressed that the changed policy while boosting the demand for vaccines immediately, doesn’t talk about how sufficient supply will be generated.

    “The bargain for limited supply between states could drive up the prices making vaccines potentially unaffordable to relatively poorer states,” said health economist Rijo M John.

    “It may limit India’s ability to contain the pandemic at the national level.” A query seeking response on the concerns expressed by health experts from the Union health ministry and health secretary remained unanswered.

    WHOPPING DEMAND-SUPPLY GAP

    Beneficiaries for Covid in India from May 1: 94 crore.

    Present production capacity of Covishield: 6.5 crore per month.

    Production of Covaxin in March: 1.5 crore per month.

  • Serum Institute prices COVID vaccine for pvt hospitals at Rs 600/dose; for state govts at Rs 400/dose

    By PTI
    NEW DELHI: Serum Institute of India (SII), the world’s largest vaccine maker, on Wednesday announced a price of Rs 600 per dose for COVID vaccine supplies to private hospitals and Rs 400 per dose to state governments.

    In a statement posted on its Twitter handle, SII said it will address the limited capacity by scaling up the vaccine production over the next two months.

    “Going ahead, 50 per cent of our capacities will be served to the Government of India’s vaccination programme, and the remaining 50 per cent of the capacity will be for the state governments and private hospitals,” it said.

    IN PICS | Remdesivir injection explained: 8 basic things to know about the high-demand COVID-19 drug

    SII said Covishield vaccine will be available to state governments for Rs 400 per dose and to private hospitals at Rs 600 per dose.